Caliper Debuts LabChip For Drug Discovery; Waits On Molecular Diagnostics
This article was originally published in The Gray Sheet
The appointment of Daniel Kisner, PhD, as chief executive officer of Caliper Technologies reflects the company's intention to keep its LabChip technology focused on pharmaceutical applications while long-term development in diagnostics continues.
You may also be interested in...
Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.